FI920450A0 - Metoder och kompositioner foer foerhindrande av symtomer av sepsis. - Google Patents

Metoder och kompositioner foer foerhindrande av symtomer av sepsis.

Info

Publication number
FI920450A0
FI920450A0 FI920450A FI920450A FI920450A0 FI 920450 A0 FI920450 A0 FI 920450A0 FI 920450 A FI920450 A FI 920450A FI 920450 A FI920450 A FI 920450A FI 920450 A0 FI920450 A0 FI 920450A0
Authority
FI
Finland
Prior art keywords
sepsis
symtomer
synthesis
over composition
antibody molecules
Prior art date
Application number
FI920450A
Other languages
English (en)
Inventor
Richard Ulevitch
Peter Tobias
Samuel D Wright
John C Mathison
Original Assignee
Scripps Clinic Res
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res, Univ Rockefeller filed Critical Scripps Clinic Res
Publication of FI920450A0 publication Critical patent/FI920450A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)
FI920450A 1989-08-01 1992-01-31 Metoder och kompositioner foer foerhindrande av symtomer av sepsis. FI920450A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38781789A 1989-08-01 1989-08-01
PCT/US1990/004250 WO1991001639A1 (en) 1989-08-01 1990-07-30 Methods and compositions for ameliorating the symptoms of sepsis

Publications (1)

Publication Number Publication Date
FI920450A0 true FI920450A0 (fi) 1992-01-31

Family

ID=23531466

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920450A FI920450A0 (fi) 1989-08-01 1992-01-31 Metoder och kompositioner foer foerhindrande av symtomer av sepsis.

Country Status (14)

Country Link
US (4) US5730980A (fi)
EP (1) EP0485430B1 (fi)
JP (1) JP2744130B2 (fi)
AT (1) ATE171042T1 (fi)
AU (1) AU645515B2 (fi)
CA (1) CA2022429C (fi)
DE (1) DE69032662T2 (fi)
DK (1) DK0485430T3 (fi)
ES (1) ES2120948T3 (fi)
FI (1) FI920450A0 (fi)
GR (1) GR1003164B (fi)
IE (1) IE902770A1 (fi)
PT (1) PT94869B (fi)
WO (1) WO1991001639A1 (fi)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645515B2 (en) * 1989-08-01 1994-01-20 Rockefeller University, The Methods and compositions for ameliorating the symptoms of sepsis
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
EP0634935A4 (en) * 1992-04-06 1996-01-31 North Shore Univ Hospital A NEW THERAPY OF SEPSIS BY MEANS OF A SOLUBLE FORM OF RECOMBINANT CD14 MYELOMONOCYTIC ANTIGEN.
WO1994028025A1 (en) * 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation
WO1995000641A1 (en) * 1993-06-17 1995-01-05 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5891618A (en) * 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
DE69534601T2 (de) * 1994-09-16 2006-08-03 The Scripps Research Institute, La Jolla Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
EP0793677A1 (en) * 1994-12-30 1997-09-10 Amgen Inc. Anti-inflammatory cd14 polypeptides
AU5688596A (en) * 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
WO1997000081A1 (en) * 1995-06-19 1997-01-03 Goyert Sanna M A method for inhibiting bacteremia and bacterial dissemination
DK0914144T3 (da) 1996-05-10 2001-04-09 Univ Texas Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
AU736096B2 (en) * 1996-05-23 2001-07-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US6093693A (en) * 1996-11-18 2000-07-25 The Wellesley Hospital Foundation B cell activation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
AU749699B2 (en) * 1998-02-07 2002-07-04 British Biotech Pharmaceuticals Limited Antibacterial agents
WO1999061468A2 (en) * 1998-05-27 1999-12-02 Gemma Biotechnology Ltd. The induction of antibiotic peptides by lait (scd14) protein
US6974698B1 (en) * 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
US6916628B1 (en) 1999-09-17 2005-07-12 Mochida Pharmaceutical Co., Ltd. Method for the measurement of soluble CD14 proteins separately
US7264967B2 (en) * 2000-11-22 2007-09-04 Mochida Pharmaceutical Co., Ltd. Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding
US20040063685A1 (en) * 2000-12-08 2004-04-01 Juji Ilzawa Combination Drugs
EP1542721A4 (en) * 2002-06-14 2007-05-02 Centocor Inc MODIFIED "S" ANTIBODIES
EP1628530B8 (en) * 2003-05-15 2012-08-01 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
CN101218251A (zh) * 2005-02-28 2008-07-09 森托科尔公司 异二聚体蛋白结合组合物
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
CN101189334B (zh) 2005-06-03 2013-11-06 持田制药株式会社 抗cd14抗体融合蛋白质
WO2015140591A1 (en) * 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
KR20200015477A (ko) * 2017-04-21 2020-02-12 임플리싯 바이오사이언스 피티와이 엘티디 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
AU645515B2 (en) * 1989-08-01 1994-01-20 Rockefeller University, The Methods and compositions for ameliorating the symptoms of sepsis

Also Published As

Publication number Publication date
AU6146190A (en) 1991-03-11
US6045795A (en) 2000-04-04
US20020034509A1 (en) 2002-03-21
US5730980A (en) 1998-03-24
IE902770A1 (en) 1991-02-27
GR1003164B (el) 1999-07-05
EP0485430B1 (en) 1998-09-16
CA2022429C (en) 1998-12-01
US6495332B2 (en) 2002-12-17
US6297049B1 (en) 2001-10-02
JPH05501399A (ja) 1993-03-18
EP0485430A4 (en) 1993-03-03
ATE171042T1 (de) 1998-10-15
PT94869B (pt) 1997-04-30
DK0485430T3 (da) 1999-06-14
PT94869A (pt) 1991-04-18
ES2120948T3 (es) 1998-11-16
DE69032662D1 (de) 1998-10-22
GR900100582A (el) 1991-12-30
CA2022429A1 (en) 1991-02-02
AU645515B2 (en) 1994-01-20
DE69032662T2 (de) 1999-03-11
WO1991001639A1 (en) 1991-02-21
JP2744130B2 (ja) 1998-04-28
EP0485430A1 (en) 1992-05-20

Similar Documents

Publication Publication Date Title
FI920450A0 (fi) Metoder och kompositioner foer foerhindrande av symtomer av sepsis.
ES2169864T3 (es) Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
FI95246B (fi) Menetelmä terapeuttisesti käyttökelpoisten, substituoitujen aminometyylibentsodihydropyraanien ja aminometyyli(di- ja tetra)hydronaftaleenien valmistamiseksi
FI930747A (fi) Heterocykliska foereningar och deras framstaellning och anvaendning
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
ATE292977T1 (de) Präsynaptische neurotoxine gegen migränekopfschmerzen
FI942345A0 (fi) Menetelmä proliiniboronaattiesterin valmistamiseksi
ATE190623T1 (de) Verwendung von steroiden zur inhibierung von angiogenesis
ATE270553T1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
FR2360558A1 (fr) Nouveaux esters de l'epinine, utiles notamment en cardiotherapie, et leur procede de preparation
DE69534601D1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
DE69327248D1 (de) Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium
ATE143009T1 (de) Neue heterocyclische carbonsäuren
FR2359153A1 (fr) Nouveaux esters carboxyliques d'acide phosphonoacetique utiles notamment pour le traitement des infections d'herpes simplex
FI911701A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-substituoitujen alkyyli-3-karboksikarbapeneemien valmistamiseksi
FR2672888B1 (fr) Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
FI94348C (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten bis-aryylifosfaattiesterijohdannaisten valmistamiseksi
ES2015349A6 (es) Metodo para producir anticuerpos inmunologicamente reactivos con angiogenina.
NO177710C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive slektede analoger
FR2536387B3 (fr) Procede de fabrication de pierres reconstituees d'apparence vieux granit et pierres obtenues par le procede
FR2303558A1 (fr) Preparation therapeutique pour traiter l'infection sous forme de pneumonie hemorragique du vison et de mastite bovine causees par la pseudomonas aeruginosa
FI911783A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-/3-(4-oksotiatsolidinyyli)/butynyyliamiinien valmistamiseksi
FR2450816A1 (fr) Nouveaux derives de la piperidine, leur procede de preparation et leur application en therapeutique
FR2401158A1 (fr) Nouvelles 3-(4-chromanylamino)-2-oxazolidinones utiles notamment comme inhibiteurs de la secretion gastrique
BE884935A (fr) Application des 4-aryl-2(1h)-quinazolinones pour le traitement des affections par autoimmunisation des tissus connectifs

Legal Events

Date Code Title Description
FD Application lapsed